Dr. Patel Discusses Checkpoint Blockade in NSCLC

Partner | Cancer Centers | <b>University of Chicago Medicine Comprehensive Cancer Center</b>

Jyoti Patel, MD, professor of medicine, director, Thoracic Oncology, University of Chicago School of Medicine, discusses checkpoint blockade in non–small cell lung cancer.

Jyoti Patel, MD, professor of medicine, director, Thoracic Oncology, University of Chicago School of Medicine, discusses checkpoint blockade in non—small cell lung cancer (NSCLC).

There have been significant responses to checkpoint blockades, but only about 20% of patients demonstrate response.

The goal now is to bring the right immunotherapy agents to a broader population, says Patel, giving more patients a chance at response.